Repurposing old drugs as antiviral agents for coronaviruses.
COVID-19
Coronavirus
Cytopathic effect
Drug repurpose
HCoV-OC43
SARS-CoV-2
Journal
Biomedical journal
ISSN: 2320-2890
Titre abrégé: Biomed J
Pays: United States
ID NLM: 101599820
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
08
05
2020
revised:
13
05
2020
accepted:
15
05
2020
pubmed:
22
6
2020
medline:
30
10
2020
entrez:
22
6
2020
Statut:
ppublish
Résumé
New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
Sections du résumé
BACKGROUND
New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2.
METHODS
FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC
RESULTS
Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC
CONCLUSION
All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
Identifiants
pubmed: 32563698
pii: S2319-4170(20)30066-4
doi: 10.1016/j.bj.2020.05.003
pmc: PMC7245249
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
368-374Informations de copyright
Copyright © 2020 Chang Gung University. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest The authors declare no conflict of interest.
Références
Vet Microbiol. 2018 Jun;219:226-233
pubmed: 29778200
Bioinformation. 2020 Mar 31;16(3):236-244
pubmed: 32308266
Antiviral Res. 2010 Nov;88(2):160-8
pubmed: 20727913
J Virol. 2011 Nov;85(21):11325-37
pubmed: 21849456
Viruses. 2018 Dec 17;10(12):
pubmed: 30562987
Toxicol Appl Pharmacol. 2017 Oct 1;332:129-137
pubmed: 28438630
Circulation. 2001 Nov 13;104(20):2417-23
pubmed: 11705818
PLoS Biol. 2018 Aug 13;16(8):e3000003
pubmed: 30102691
Diseases. 2016 Jul 25;4(3):
pubmed: 28933406
J Crit Care. 2020 Jun;57:279-283
pubmed: 32173110
J Vet Med Sci. 1992 Jun;54(3):557-62
pubmed: 1322718
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):530-3
pubmed: 23790799
PLoS One. 2015 Apr 21;10(4):e0124595
pubmed: 25897961
Biosci Trends. 2020 May 21;14(2):156-158
pubmed: 32281583
Antiviral Res. 2020 May;177:104762
pubmed: 32147496
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Viruses. 2018 Nov 01;10(11):
pubmed: 30388745
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Trop Med Int Health. 2020 Mar;25(3):278-280
pubmed: 32052514
J Virol. 2019 May 29;93(12):
pubmed: 30918074
Evid Based Complement Alternat Med. 2005 Jun;2(2):209-215
pubmed: 15937562
J Med Chem. 2012 Dec 13;55(23):10363-77
pubmed: 23167614
Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246
pubmed: 32247211
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
J Feline Med Surg. 2004 Apr;6(2):131-2
pubmed: 15123159
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
pubmed: 22446091
One Health. 2020 Mar 27;9:100128
pubmed: 32258351
Pharmaceuticals (Basel). 2020 Mar 21;13(3):
pubmed: 32245264
Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25
pubmed: 15144898
Travel Med Infect Dis. 2019 Jul - Aug;30:9-18
pubmed: 31252170
Am J Vet Res. 1976 Dec;37(12):1449-53
pubmed: 793459
Toxicol Appl Pharmacol. 2018 Oct 1;356:90-97
pubmed: 30053394
Antimicrob Agents Chemother. 2001 May;45(5):1473-9
pubmed: 11302813
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Antiviral Res. 2020 May;177:104760
pubmed: 32135219
Future Virol. 2011 May;6(5):615-631
pubmed: 21765859